ISCOM technology-based Matrix M adjuvant: success in future vaccines relies on formulation.

摘要

Adjuvant development is driven by the need to improve immune responses to vaccine antigens without increasing side effects beyond an acceptable level. Adjuvant use in human vaccines has been both limited and cautious and, until the last decade, only aluminum salt adjuvants were approved. In animal vaccines, however, several adjuvants and antigen-presentation systems have been used, including plain saponins, immune-stimulating complexes (ISCOMs), matrix, montanide oils, carbo-pol formulations, poxvirus constructs and DNA-based formulations. Here, we show that the novel and widely tested saponin based Matrix M~(? )(IsconovaAB, Uppsala, Sweden) adjuvant formulation is ready for application in humans.